色婷婷综合成人av_99久久精品国产毛片_成人一区二区在线_国产91丝袜在线播放_久久人人爽人人爽人人片av免费_欧美伊人

德國 JPT   
JPT Peptide Technologies是BioNTech AG 子公司.2004年從Jerini AG獨立出來.


JPT Peptide Technologies a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), is a DIN EN ISO 9001:2008 certified research and development partner and innovative service and tool provider for peptide related projects. JPT’s key technologies: SPOT? – for ultra-high-throughput peptide synthesis and screening, PepStar? – for high-content peptide microarrays, PepTrack? – for flexible peptide library assembly, PepMix? – for antigen specific T-cell stimulation using peptide pools, and SpikeTide? – for protein biomarker quantification, accelerate research in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimization, enzyme profiling and proteomics.


JPT Peptide Technologies GmbH was established in 2004 as a spin-off of Jerini AG, a Berlin based peptide drug discovery company. In 2008, JPT became a wholly owned subsidiary of BioNTech AG, Mainz (Germany), a company that develops novel immune therapy and diagnostic approaches for various cancers.

JPT Peptide Technologies GmbH is a leading provider of innovative peptide-based services and research tools, as well as a research and development partner for projects dealing with peptide discovery, qualification and optimization in various applications fields.
JPT's head office and production sites are located in Berlin, Germany. All of its products are manufactured in Berlin in accordance with DIN EN ISO 9001:2008 guidelines.

Together with its US-subsidiary based in Acton, near Boston, Massachusetts, JPT is serving a worldwide customer base in the pharmaceutical and biotechnology industries, as well as researchers in universities, governmental and non-profit organizations. Over the past decade, JPT has developed a portfolio of proprietary technologies and a series of unique products and services which support research efforts in proteomics as well as in all development phases of novel vaccines against infectious and autoimmune diseases, as well as against allergies and cancer.

Since 2009, JPT is actively involved in R&D partnerships and contract research projects focusing on seromarker discovery & validation, development of immune monitoring tools and diagnostics, vaccine target discovery, peptide lead identification & optimization, biomarker quantification by targeted proteomics, enzyme substrate identification & sensitivity profiling.

In 2011, JPT launched a webshop platform to ease the access to its unique portfolio of catalog peptide microarrays, peptide pools and intelligent peptide collections.

JPT today has achieved world-wide credibility as an one-stop-source and development partner for all peptide related projects.